Response Biomedical Corp
			Symbol			RBM
			Shares Issued			254,672,008
			Close 2009-11-10			C$ 0.135
			Recent Sedar Documents

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Response Biomedical narrows Q3 loss to $3.17-million

2009-11-10 16:47 ET - News Release

Mr. Bill Wickson reports

RESPONSE BIOMEDICAL CORPORATION ANNOUNCES THIRD QUARTER RESULTS

Response Biomedical Corp. today released financial results for the third quarter and nine months ended Sept. 30, 2009.

Total revenues for the three- and nine-month periods ended Sept. 30, 2009, increased 39 per cent and 106 per cent to $2,047,523 and $7,495,339, respectively, compared with $1,471,130 and $3,641,766 for the same periods in 2008. Given the success of the company's commercial partners' efforts, clinical products revenue showed the largest growth at 62 per cent and 139 per cent to $1,688,423 and $5,236,438 for the three- and nine-month periods ended Sept. 30, 2009, respectively, compared with $1,040,649 and $2,191,409 for the same periods in 2008.

Net loss for the three- and nine-month periods ended Sept. 30, 2009 was reduced by 14 per cent and 38 per cent to $3,177,221 and $6,807,623, respectively, compared with $3,684,602 and $10,969,207 for the same periods in 2008. Expenses were reduced by 15 per cent and 29 per cent to $2,813,195 and $7,552,556, respectively, for the three- and nine-month periods ended Sept. 30, 2009, compared with $3,294,694 and $10,636,832 for the same periods in 2008.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.